جستجوی استاد راهنمای دانشگاهی

Gordon Lowe is an Honorary Senior Research Fellow at the University of Glasgow's School of Cardiovascular & Metabolic Health. He holds a DSc from Glasgow University (2006) and has been recognized with prestigious awards, including the Kettle Lecture (2006) and the Investigator Award from the International Society of Thrombosis and Haemostasis (2009). His research focuses on vascular diseases (coronary heart disease, stroke, peripheral arterial disease, venous thrombosis) and haemostasis, particularly in relation to haemophilia. He led the Haemostasis and Thrombosis Research Laboratory from 1987, contributing to clinical trials and epidemiological studies on thrombotic and haemorheological factors. Education: MB, ChB (with Honours and gold medal) from the University of St. Andrews (1972). Postgraduate training in internal and vascular medicine at Dundee, Nottingham, and Glasgow. Career highlights include serving as Professor of Vascular Medicine at Glasgow University (1993–2009) and continuing as an Emeritus Professor. Research interests include the interplay between haemostatic factors and cardiovascular outcomes, with over 550 refereed publications. He chairs editorial boards for journals like Journal of Thrombosis and Haemostasis and contributes to clinical guidelines through the Scottish Intercollegiate Guidelines Network (SIGN). Professional roles include past presidency of the British Society for Haemostasis and Thrombosis, and active participation in clinical trial committees. Scientific contributions span meta-analyses of coagulation factors, epidemiological studies on VTE risk, and historical analyses of thrombosis. He is affiliated with the Diabetes, Renal, Endocrine, and Metabolic Medicine Research Theme within his school.

• Vascular Medicine
• Haemostasis
• Thrombosis
• +۳ مورد دیگر

Dr. Sarah Jones is an Associate Professor in Thrombosis and Haemostasis at Manchester Metropolitan University, serving as Deputy Director of Research for the Department of Life Sciences. She leads the Thrombosis Group and holds an honorary Reader position at the University of Manchester. Academic Affiliation: Manchester Metropolitan University Secondary Appointment: University of Manchester (Honorary Reader) Over 20 years, Dr. Jones has pioneered research on platelet signaling pathways and their role in thrombosis. Her current work focuses on platelet-endothelial crosstalk in disease states, with emphasis on in vitro thrombosis modeling to replace animal testing. This research, funded by BBSRC, NC3Rs, and BHF, addresses cardiovascular disease mechanisms and translational antithrombotic testing. Her scientific publications demonstrate expertise in platelet biology (Pim kinase signaling, SIRT1 regulation, proteoglycan interactions) and thrombosis modeling. Recent work includes placental perfusion studies for pregnancy-related cardiovascular complications. Grants & Projects: UKRI (NC3Rs) Partnership and Impact Award (2025-2026) UKRI BBSRC/NC3Rs grant for human haemostasis models (2023-2025) British Heart Foundation collaborations (2021-2025) Dr. Jones supervises PhD students (Mishaal Reyman, Poppy White, etc.) and teaches on Biomedical Science, Cellular Science, and Clinical Haematology programs. She has developed innovative endothelialised in-vitro thrombosis models that reduce animal usage in cardiovascular research.

• Thrombosis
• Haemostasis
• Platelet Biology
• +۳ مورد دیگر

Associate Professor Freda Passam is a Clinical Academic Haematologist at Royal Prince Alfred Hospital, University of Sydney, specializing in thrombosis and haemostasis. She leads the Haematology Research Group at the Charles Perkins Centre, focusing on platelet biology, endothelial cell dysfunction, and translational research in cardiovascular diseases. Her work integrates basic science with clinical applications, including developing microfluidic technologies like the Endo-chip for thrombosis diagnosis and therapy screening. Education: MD and PhD in Greece (angiogenesis in Hodgkin’s lymphoma), postdoctoral training at UNSW and Harvard University. Research spans platelet hyperactivity in diabetes, immune thrombosis (e.g., HIT), and thiol isomerase inhibitors as antithrombotics. Collaborates globally with institutions like Harvard and the University of Utah. Research Interests: 1) Platelet biomarkers in diabetes-related cardiovascular risk; 2) Immune thrombosis diagnostics/therapies (e.g., Endo-chip); 3) Bone marrow-on-chip models for thrombopoiesis. Current projects include SEC61B regulation of calcium flux, endothelial thromboinflammation, and ERp5/ERp57 roles in platelet production. Grants: Over $6M in funding from NHMRC, MRFF, NSW Health, and industry partnerships. Notable awards include Sydney Nano Grand Challenge Award (2022) and SLHD VTE Stewardship Award (2020). Advising: Mentors over 6 PhD/master’s students in thrombosis research, emphasizing clinical/research integration. Teaching includes Sydney Medicine curriculum, bedside tutorials, and student engagement in lab activities. Labs/Teams: Haematology Research Group (Charles Perkins Centre), collaborations with Sydney Health Partners, Harvard, and international haematology groups. Develops technologies like the Endo-chip and bone marrow-on-chip models.

• Thrombosis
• Cardiovascular diseases
• Endothelial cell biology
• +۷ مورد دیگر

Dr. Tom McKinnon is an Associate Professor in Thrombosis and Haemostasis within the Department of Immunology and Inflammation, Faculty of Medicine at Imperial College London. His research focuses on Von Willebrand Factor (VWF), thrombosis, haemostasis, and anti-thrombotic targets, with affiliations including the Centre for Haematology, Centre for Advanced Therapeutics, and Vascular Science Network. PhD research on VWF glycosylation under Professor Mike Laffan at Imperial Current projects include VWF interactions as drug targets and thromboplastics research funded by MRC Collaborates with Imperial’s School of Public Health, National Heart and Lung Institute, and Common Seas His scientific awards include a BHF Intermediate Basic Science Fellowship and MRC project grant. Research funding also comes from Kidney Research UK, Imperial Health Charity, and Apollo Therapeutics. He leads an MRes in Experimental Molecular Biosciences (launching 2026) and contributes to Imperial’s BSc in Haematology and MSc pathways.

• Thrombosis
• Haemostasis
• Cardiorespiratory Medicine and Haematology
• +۵ مورد دیگر

Manu Shankar Hari is a triple-doctorate clinical academic (MB BS MD PhD[immunology] MSc[Epidemiology]) holding specialist fellowships in anaesthesia, intensive-care medicine and epidemiology (FRCA EDIC FFICM). His research fingerprint centres on COVID-19 immunopathology, post-COVID-19 syndromes, sepsis-related platelet biology and T-cell immunosenescence, evidenced by >350 citations and leadership of large UK consortium studies such as PHOSP-COVID and ISARIC4C. Education & Qualifications: MB BS – primary medical degree MD – higher medical doctorate PhD in Immunology MSc in Epidemiology FRCA – Fellowship of the Royal College of Anaesthetists EDIC – European Diploma of Intensive Care Medicine FFICM – Fellowship of the Faculty of Intensive Care Medicine Research Interests: Dr Hari’s work integrates bedside critical care with translational immunology. He interrogates how accelerated immune ageing shapes COVID-19 severity, delineates platelet–immune crosstalk in sepsis, and identifies determinants of recovery from post-COVID-19 dyspnoea using multicentre prospective cohorts and randomised trials. Publication Trends: Recent first-author or senior-author papers in Immunity & Ageing , The Lancet Respiratory Medicine , The Lancet Regional Health – Europe , Shock and JAMA reveal a coherent programme spanning immunosenescence, antiplatelet therapy in COVID-19, and long-COVID respiratory sequelae. Collaborations & Funding: He leads or co-leads national UK consortium grants (PHOSP-COVID, ISARIC4C) involving hundreds of investigators and institutions, supported by NIHR/MRC/UKRI funding streams, with extensive international collaboration networks.

• COVID-19
• Immunology
• Critical Care Medicine
• +۵ مورد دیگر

Professor Denise Jackson is a faculty member in the Department of Health and Biomedical Sciences at RMIT University, Bundoora West campus. She serves as the Head of the Thrombosis and Vascular Biology laboratory and holds an honorary fellowship from the National Health and Medical Research Council (NHMRC). Her research focuses on thrombosis mechanisms, platelet biology, and immunoreceptor roles in infection and immunity. She coordinates courses such as MEDS1142 Medical Informatics, BUSM3220 Medical Laboratory Quality Systems, and ONPS2153 Medical Informatics and Laboratory Management. Research Interests: Professor Jackson’s work spans thrombosis, platelet function, mouse models of thrombus formation, and the molecular mechanisms of immunoreceptors in pathogens. Her team investigates tetraspanins’ role in blood clot regulation and signaling pathways in platelets. Key projects include studying tyrosine kinase inhibitors’ effects on haemostasis and exploring immunoreceptor crystal structures for drug design. Professional Involvement: She reviews grants for NHMRC, National Heart Foundation, and international bodies like the Wellcome Trust and NSF. She also serves as a reviewer for journals including Nature and Blood . Student Supervision: Principal supervisor of 12 Honours, 3 Masters, and 4 PhD students. Labs/Teams: Leads the Thrombosis and Vascular Biology lab, collaborating on drug development and thrombosis prevention strategies.

• Thrombosis
• Haematology
• Cardiovascular Medicine
• +۵ مورد دیگر

PD Dr Maya André serves as Deputy Head of the Paediatric Intensive Care Service (IPS) at the University Children’s Hospital Basel (UKBB) , Switzerland, and is a physician-scientist with venia legendi in Paediatrics from the University of Tübingen. She concurrently directs her own research laboratory at the University Children’s Hospital Tübingen , Department I Haematology & Oncology, focusing on anti-leukaemic NK-cell immunotherapy. Education & Training MD, Universities of Bonn, Freiburg & Vienna (1990-1996) Dr. med., University Children’s Hospital Freiburg – thesis on Valproate and haemostasis (1998) Specialist certificate in Paediatrics (2002) Additional qualification in Paediatric Intensive Care Medicine (2005) Specialisation in Neonatology (2006) Dr. rer. nat., Faculty of Mathematics & Natural Sciences, Tübingen – thesis on Functional conversion of bacterially reprogrammed monocytes (2012) Habilitation & venia legendi in Paediatrics, University of Tübingen – thesis on Donor-patient-specific xenotransplantation model for NK-cell graft-versus-leukaemia reactivity (2016) Research Focus Maya André’s scientific work bridges bedside paediatric intensive care with cutting-edge cellular immunology. Her laboratory pioneered patient-specific zebrafish and murine xenograft models to dissect how natural killer (NK) cells eradicate acute leukaemia. She has advanced the concept of tumor-priming to generate memory-like NK cells with enhanced anti-tumour activity and currently investigates TIGIT-CD155 blockade to potentiate NK-92 and cytokine-induced memory-like NK cell therapies. Her translational studies integrate multi-parameter flow cytometry panels, real-time intravital imaging, and rigorous pre-clinical validation in preparation for first-in-child trials. Scientific Awards & Funding Sponsorship Prize, Society for Neuropaediatrics (1995) Continuous third-party funding since 2010 totalling 1.5 million CHF from: German Research Foundation, Jose-Carreras Foundation, Else-Kröner-Fresenius Foundation, Fortüne Programme (Tübingen), Madeleine-Schickedanz Foundation, German Childhood Cancer Foundation, Manchot Foundation. Professional Memberships German Society for Paediatrics (DGKJ) Reviewer for Blood, Epilepsy, Haematologica, Plos One, International Journal of Cancer, Journal of Leukocyte Biology, Human Immunology, Leukaemia Research Laboratory & Clinical Team She heads a dedicated research group located at the University Children’s Hospital Tübingen, collaborating closely with the Departments of Paediatric Haematology & Oncology and the Centre for Translational Immunology (CTI). The team includes post-doctoral scientists, graduate students, and clinical fellows who straddle bench-to-bedside research pipelines.

• Paediatric Intensive Care
• Neonatology
• NK-cell immunology
• +۳ مورد دیگر

Dr. Al Edwards is a Professor in the Department of Pharmacy within the School of Chemistry, Food and Pharmacy at the University of Reading. His extensive research portfolio spans over two decades, with a clear evolution from immunology and dendritic cell biology in his earlier career to his current focus on microfluidic diagnostic devices and point-of-care testing technologies. Professor Edwards' research interests center on developing innovative diagnostic solutions, particularly in microfluidics and point-of-care testing. His work bridges engineering and clinical applications, with significant contributions to antibiotic susceptibility testing, vaccine delivery systems, and smartphone-based diagnostic platforms. His research has evolved from fundamental immunological studies to highly applied diagnostic device development, demonstrating a strong translational research trajectory. His publication record shows a clear trend toward practical diagnostic solutions with clinical applications, particularly in antibiotic susceptibility testing and point-of-care diagnostics. The integration of microfluidics, 3D printing, and smartphone technology represents the cutting edge of his current research, with numerous publications demonstrating how these technologies can be combined to create accessible diagnostic tools for resource-limited settings. Professor Edwards has been actively involved in mentoring researchers and collaborating across disciplines, as evidenced by his numerous co-authored publications. His work on diagnostic device usability and information design for self-testing demonstrates attention to the practical implementation challenges of diagnostic technologies. His laboratory appears to specialize in developing open-source, low-cost diagnostic platforms using Raspberry Pi systems, 3D printing, and microcapillary technologies. The Cygnus platform for smartphone-based diagnostics and the PiRamid imaging system represent significant contributions to making sophisticated diagnostic technologies more accessible.

• Microfluidics
• Point-of-care diagnostics
• Antibiotic susceptibility testing
• +۴ مورد دیگر

Tine Goedhart is a Researcher in the Department of Pediatrics at Erasmus University Medical Center Rotterdam, specializing in pharmacokinetics, haemophilia, and platelet research. Her work is closely associated with the SYMPHONY consortium, the Thrombocytopathy in the Netherlands (TiN) Study Group, and the OPTI-CLOT study group, focusing on thrombosis and haemostasis. Her research spans Pharmacokinetics , Haemophilia A/B , Blood Clotting Factor 8 , and Platelet Biochemistry . Key areas include optimizing factor concentrate dosing in haemophilia, developing rapid diagnostic tests for platelet disorders, and investigating endothelial cell heterogeneity in vascular diseases. Her work integrates pharmacological modeling with clinical applications to improve treatment strategies for bleeding disorders through: Pharmacokinetic-guided prophylaxis dosing Nanobody-based platelet agonist development Transcriptional profiling of endothelial colony-forming cells Population modeling for pediatric hemophilia B Analysis of her 14 research outputs reveals dominant trends in thrombosis diagnostics , factor replacement therapy optimization , and pediatric pharmacokinetics , with strong emphasis on translational applications for hemophilia management and platelet function disorders. Dr. Goedhart collaborates extensively with international consortia including SYMPHONY, TiN, and OPTI-CLOT, contributing to multi-center studies on haemophilia management and platelet function. While specific grant details are not provided, her research is embedded within these large-scale collaborative projects focused on advancing bleeding disorder treatments. She actively participates in the SYMPHONY consortium and TiN study group, which drive innovation in thrombotic/bleeding disorder research through integrated pharmacokinetic and functional analyses across European institutions.

• Pharmacokinetics
• Haemophilia
• Platelet Research
• +۳ مورد دیگر

Dr. Jamie O'Sullivan is a Lecturer and Principal Investigator at the Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI). Her research focuses on the bidirectional interactions between coagulation pathways and cancer metastasis, particularly involving von Willebrand Factor (VWF) in diseases like cancer, malaria, and inflammatory conditions. She holds a BSc in Biomedical Science from University College Cork and a PhD in Haematology from Trinity College Dublin, supported by an Irish Research Council scholarship. Notable awards include the 2018 Martin Villar Haemostasis Award and a Novartis Fellowship. Education: PhD in Haematology, Trinity College Dublin (2015) BSc Biomedical Science, University College Cork (Ireland) BSc Biomedical Science, Cork Institute of Technology (Ireland) Research Interests: Her work explores VWF's roles in cancer metastasis, thrombosis, and vascular biology. Key areas include VWF clearance pathways, endothelial-tumor interactions, and therapeutic targeting of VWF in diseases like multiple myeloma and breast cancer. Grants & Funding: Her lab is supported by grants from Science Foundation Ireland, the Irish Research Council, and industry collaborations. Ongoing projects include studies on the VWF-ADAMTS13 axis in cancer-associated thrombosis and the role of tinzaparin in breast cancer metastasis. Awards: 2018 Martin Villar Haemostasis Award Novartis Fellowship (2017–2019) Labs & Teams: The O'Sullivan Lab is part of the Irish Centre for Vascular Biology, collaborating with international groups like KU Leuven University. She also leads the StAR Programme in RCSI, training future researchers in vascular biology.

• Vascular Biology
• Hematology
• Cancer Biology
• +۵ مورد دیگر

Alessio Branchini is an Associate Professor in the Department of Life Sciences and Biotechnology at the University of Ferrara. His research focuses on protein engineering, molecular mechanisms, and coagulation factors with particular emphasis on hemophilia and related blood disorders. Dr. Branchini's research interests span protein engineering, molecular mechanisms of coagulation factors, fusion protein technology, and ribosome readthrough. He investigates how genetic mutations affect coagulation proteins, particularly factor IX in hemophilia B, and develops molecular approaches to correct these defects. His work combines structural biology, molecular genetics, and therapeutic development to address bleeding disorders. His publication record shows a strong focus on coagulation factors, particularly factor IX and VIII, with recent work exploring translational readthrough mechanisms, splice site corrections using engineered U1snRNAs, and CRISPR-based approaches to activate coagulation gene promoters. His research bridges basic molecular mechanisms with potential therapeutic applications for hemophilia and related disorders. Dr. Branchini has published extensively in top hematology and molecular biology journals including Journal of Thrombosis and Haemostasis, where he has contributed numerous articles on coagulation factor mechanisms and therapeutic approaches. His collaborative work with researchers like Pinotti M, Bernardi F, and others demonstrates a strong research network focused on bleeding disorders.

• Protein engineering
• Molecular mechanisms
• Coagulation factors
• +۵ مورد دیگر

Carolina Guillén Rienda is a Specialist in Hematology and Hemotherapy affiliated with the University of Navarra Clinic Cancer Center. She works at the Madrid Headquarters and is actively involved in research and teaching. Her educational background includes graduating in Medicine from the Autonomous University of Madrid in 2008. Subsequently, she specialized in Hematology and Hemotherapy at the University Hospital of Móstoles in Madrid in 2015. Research focus on thromboembolic disease and coagulopathies (bleeding disorders) Current research: exploring new applications of global tests in the Hemostasis Laboratory Teaching role: Coordinator and instructor for training Hematology and Hemostasis laboratory technicians at BR Salud Central Laboratory and Ramón y Cajal Hospital She has presented multiple oral and written contributions at national conferences and two internationally. Professional affiliations include membership in the Spanish Society of Hematology and Hemotherapy (SEHH), Spanish Society of Thrombosis and Hemostasis (SETH), European Society of Hematology (EHA), and International Society on Thrombosis and Haemostasis (ISTH).

• Hematology
• Thromboembolic Disease
• Coagulopathies
• +۲ مورد دیگر

Dr. Manfred Maitz serves as a Research Fellow and Group Leader at the Leibniz Institute of Polymer Research Dresden (IPF), specifically within the Max Bergmann Center of Biomaterials under the Division Polymer Biomaterials Science. He holds a secondary appointment as Guest Professor at Southwest Jiaotong University's School of Materials Science and Engineering in Chengdu, China, where he conducts annual research stays. His career spans institutions in Würzburg, Ulm, Magdeburg, Dresden, and Chengdu since the early 2000s. Dr. Maitz's research centers on hemocompatible surfaces for blood-contacting medical devices, with focus on feedback-responsive materials that regulate blood coagulation and inflammatory responses. His work targets critical applications including vascular stents, artificial heart valves, hemodialysis membranes, and extracorporeal circulation tubings. Recent publications demonstrate leadership in developing FXa-responsive hydrogels , heparin-releasing coatings , and platelet-mimetic surfaces that dynamically interact with blood components. Analysis of his 15 most recent articles (2023-2025) reveals dominant themes in stimuli-responsive anticoagulation , biomimetic surface engineering , and blood-material interaction mechanisms . His team frequently employs hydrogel-based delivery systems triggered by coagulation factors, with increasing focus on cancer-biomaterial interfaces and advanced in vitro blood models . Methodologically, his work bridges polymer chemistry, surface science, and translational hematology. As a recognized expert, he participates in the WTR (Working Group on Thrombosis and Hemostasis Research) at IPF and maintains active memberships in major societies including the Society for Biomaterials, German Society for Biomaterials, American Heart Association, and International Society on Thrombosis and Haemostasis. While specific awards aren't documented in the source material, his sustained leadership in high-impact journals like Nature Communications , Biomaterials , and Advanced Science underscores significant contributions to the field. Dr. Maitz's collaborative network spans Germany, China, and international institutions, with frequent co-authorship on vascular biomaterial projects. His group develops specialized in vitro blood flow models and hemocompatibility testing platforms that address limitations of static assays. Current work emphasizes clinical translation of responsive coatings for neurovascular implants and pancreatic cancer microenvironment modeling.

• Biomaterials
• Hemocompatibility
• Blood Coagulation
• +۴ مورد دیگر

Ruben Bierings is an Associate Professor in the Department of Hematology at Erasmus University Medical Center (Erasmus MC) in Rotterdam, Netherlands. His research focuses on the molecular mechanisms of von Willebrand factor (VWF) secretion and Weibel-Palade body (WPB) biogenesis in endothelial cells, aiming to understand bleeding disorders like von Willebrand disease (VWD). Education: PhD from Utrecht University (2007, thesis on VWF secretion in endothelial cells). Career: Postdoctoral MRC Fellow at NIMR (2007-2011), Group Leader at Sanquin Research (2013-2018), and Principal Investigator at Erasmus MC (2018-present). His lab uses patient-derived endothelial colony-forming cells (ECFCs) to study WPB formation, exocytosis, and VWD pathogenic mechanisms. Key molecular players include Rab GTPases, Rab effectors, and SNARE proteins. Collaborations span clinical partners at Erasmus MC (Prof. Frank Leebeek and Prof. Marjon Cnossen) and external institutions such as Sanquin Research, Leiden University Medical Center, and the NWO-funded SYMPHONY consortium. He co-chairs the International Society for Thrombosis and Haemostasis (ISTH) Vascular Biology Scientific Standardization Subcommittee and serves on the Scientific Advisory Board of Trombosestichting Nederland (TSN). His work aims to develop personalized therapies for VWD patients through gene correction and gene therapy strategies.

• Endothelial Cell Biology
• Von Willebrand Factor Biosynthesis and Secretion
• Weibel-Palade Body Biogenesis
• +۵ مورد دیگر

Patrik Benjaminsson Nyberg is an Adjunct Associate Professor at Linköping University's Department of Biomedical and Clinical Sciences (BKV), within the Division of Clinical Chemistry and Pharmacology (KKF). He focuses on interdisciplinary research at the intersection of forensic science, clinical pharmacology, and emergency medicine. His work includes developing AI-driven methodologies for solving crimes using postmortem metabolomics, predicting neurotoxicity from cancer treatments, and advancing rapid narcotics classification techniques. Research interests span emergency medicine innovations like hyperspectral imaging for triage optimization, forensic toxicology, and the application of machine learning in crime scene analysis. His team has secured significant grants, including SEK 13 million from the Swedish Research Council for AI-based forensic research. He is affiliated with the Emergency Medicine Research Center and collaborates on projects involving vascular calcification and ER stress responses in disease. Key Projects: Postmortem metabolomics AI systems, taxane neurotoxicity prediction tools Labs/Teams: Emergency Medicine Research Center, Haemostasis Research Group Grants: SEK 13M Swedish Research Council (2023), WCMM funding (2024)

• Emergency Medicine
• Forensic Sciences
• Clinical Pharmacology
• +۳ مورد دیگر